-
Mashup Score: 20Teclistamab: real-world safety and efficacy - 11 hour(s) ago
Here, we summarize a retrospective analysis presented by Dima at the 65th American Society of Hematology Annual Meeting and Exposition evaluating the safety and efficacy of teclistamab in the real-world setting.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Dual antigen targeting immunotherapies in MM - 3 day(s) ago
Here we summarize a presentation by Sham Mailankody from the International Myeloma Society’s 5th Immune Effector Cell Therapies in Multiple Myeloma Workshop, 2024, on the dual antigen-targeting CAR T cells and trispecific antibodies in MM.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Symposium | BCMA-directed bispecific antibodies - 3 day(s) ago
During the Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Lea…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12
During the International Myeloma Society 5th Immune Effector Cell Workshop, the Multiple Myeloma Hub was pleased to speak to Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US. We asked, What is the rationale for T-cell therapies in the treatment of smoldering MM?
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Symposium | Q&A session - 9 day(s) ago
The Multiple Myeloma Hub virtual symposium held on March 11, 2024 entitled “Current and future perspectives for bispecific antibodies in multiple myeloma: Le…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12European Commission approves cilta-cel for the treatment of RRMM after ≥1 prior LOT - 10 day(s) ago
On April 22, 2024, the EC granted approval to cilta-cel for the treatment of RRMM after one or more prior therapies, including an IMiD or PI, who are lenalidomide-refractory with disease progression on the last therapy.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet-
🚨 NEWS 🚨 @EU_Commission approves cilta-cel for the treatment of relapsed/refractory #MultipleMyeloma after ≥1 prior therapy, including an IMiD or PI, who are lenalidomide-refractory with disease progression on the last therapy. Read more: https://t.co/BUz3NRL77J #Myeloma… https://t.co/jlU26eqUMI https://t.co/uzmrCMo348
-
-
Mashup Score: 4Antigen escape as a mechanism of resistance to T-cell-engaging therapies in multiple myeloma - 10 day(s) ago
Here, we summarize a presentation by Paola Neri on the mechanisms of antigen escape after T-cell-redirecting therapies, presented at the 5th Immune Effector Cell Therapies in Multiple Myeloma Workshop.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
On March 11, 2024, the Multiple Myeloma Hub hosted a virtual symposium, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learn…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy? - 14 day(s) ago
The Multiple Myeloma Hub and Lymphoma Hub were pleased to speak to Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy?
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 23Symposium | BCMA-directed bispecific antibodies - 15 day(s) ago
During the Multiple Myeloma Hub virtual symposium, Naresh Bumma, The Ohio State University, Columbus, US, delivered a presentation on BCMA-directed bispecific antibodies in MM.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet-
In our recent symposium, Naresh Bumma delved into BCMA-directed #bispecific antibodies for MM. “We need to consider patient-specific clinical factors. Access is very important, and obviously patient preference is very important.” Catch up below 👇 https://t.co/TunXO7MHUG https://t.co/kEoaJwZphF
-
What is the safety and efficacy of teclistamab for the treatment of relapsed/refractory multiple myeloma in the real-world setting? Check out our summary of the expert presentation by @DimaDana from #ASH23 👉 https://t.co/jJuItxa2db #MultipleMyeloma #MMsm #MedicalEducation https://t.co/InBGYUv80m